# Overview
Bevacizumab is a vascular Endothelial Growth Factor (VEGF) inhibitor indicated for multiple cancers.

Note: Avastin for ocular diagnoses are found on a separate criteria document

## Coverage Guidelines
Authorization may be granted for members new to AllWays Health Partners who are currently receiving treatment with Avastin, Mvasi or Zirabev excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

**OR**
Authorization may be granted when the following have been met:

1. Colorectal cancer (CRC)
   a. The member has a diagnosis of colorectal cancer, including small bowel adenocarcinoma, appendiceal carcinoma, and anal adenocarcinoma
   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabev

2. Non-small cell lung cancer (NSCLC)
   a. The member has a diagnosis of recurrent, advanced, or metastatic non-squamous NSCLC
   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabev

3. CNS cancer
   a. The member has ONE of the following diagnosis:
      i. Glioblastoma

---

<table>
<thead>
<tr>
<th>Plan</th>
<th>☐ MassHealth</th>
<th>☑ Commercial/Exchange</th>
<th>Program Type</th>
<th>☑ Prior Authorization</th>
<th>☑ Quantity Limit</th>
<th>☐ Step Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefit</td>
<td>☐ Pharmacy Benefit</td>
<td>☑ Medical Benefit (NLX)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialty Limitations</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Specialty Medications</th>
<th>All Plans</th>
<th>Phone: 866-814-5506</th>
<th>Fax: 866-249-6155</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Non-Specialty Medications</th>
<th>MassHealth</th>
<th>Phone: 877-433-7643</th>
<th>Fax: 866-255-7569</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Commercial</td>
<td>Phone: 800-294-5979</td>
<td>Fax: 888-836-0730</td>
</tr>
<tr>
<td></td>
<td>Exchange</td>
<td>Phone: 855-582-2022</td>
<td>Fax: 855-245-2134</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medical Specialty Medications (NLX)</th>
<th>All Plans</th>
<th>Phone: 844-345-2803</th>
<th>Fax: 844-851-0882</th>
</tr>
</thead>
</table>

| Exceptions | N/A |
ii. Intracranial and spinal ependymoma (excludes sub-ependymoma)

iii. Anaplastic gliomas

iv. Low-grade (WHO Grade II) infiltrative supratentorial astrocytoma/oligodendroglioma

v. Medulloblastoma

vi. Primary central nervous system lymphoma

vii. Meningiomas

viii. Limited and extensive brain metastases

ix. Leptomeningeal metastases

x. Metastatic spine tumors

b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

4. Ovarian cancer/Fallopian tube cancer/Primary peritoneal cancer

   a. Member has a diagnosis of the following types of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer:

      i. Epithelial ovarian cancer, including: Carcinosarcoma (malignant mixed Müllerian tumors)

      ii. Clear cell carcinoma

      iii. Mucinous carcinoma

      iv. Grade 1 endometrioid carcinoma

      v. Low-grade serous carcinoma

      vi. Borderline epithelial tumors (low malignant potential) with invasive implants

      vii. Malignant sex cord-stromal tumors

      viii. Fallopian tube cancer

      ix. Primary peritoneal cancer

b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

5. Uterine/Endometrial cancer

   a. The member has a diagnosis of progressive, advanced, or recurrent uterine cancer or endometrial cancer

   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

6. Cervical/Vaginal cancer

   a. The member has a diagnosis of persistent, recurrent, or metastatic cervical or vaginal cancer

   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

7. Breast cancer

   a. The member has a diagnosis of breast cancer

   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

8. Renal cell carcinoma

   a. The member has a diagnosis of relapsed or metastatic renal cell carcinoma

   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

9. Soft tissue sarcoma

   a. The member has a diagnosis of soft tissue sarcoma

   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe
10. Angiosarcoma  
   a. The member has a diagnosis of angiosarcoma, as single agent therapy.  
   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

11. Solitary fibrous tumor/hemangiopericytoma  
   a. The member has a diagnosis of solitary fibrous tumor or hemangiopericytoma, in combination with temozolomide  
   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

12. Malignant pleural mesothelioma  
   a. The member has a diagnosis of malignant pleural mesothelioma, in combination with pemetrexed and either cisplatin or carboplatin, followed by single agent maintenance therapy  
   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

13. AIDS-related Kaposi sarcoma  
   a. The member has a diagnosis of AIDS-related Kaposi sarcoma  
   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

14. Vulvar cancer  
   a. The member has a diagnosis of unresectable locally advanced, recurrent, or metastatic vulvar cancer.  
   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

15. Peritoneal mesothelioma  
   a. The member has a diagnosis of peritoneal mesothelioma  
   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

16. Tunica vaginalis testis mesothelioma  
   a. The member has a diagnosis of tunica vaginalis testis mesothelioma.  
   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

17. Hepatocellular carcinoma  
   a. The member has a diagnosis of hepatocellular carcinoma, in combination with atezolizumab  
   b. For **Avastin**: The member has had an inadequate response or intolerance to Mvasi and Zirabe

**Continuation of Therapy**  
Reauthorization requires physician documentation of improvement of member’s condition.

**Limitations**  
1. Initial approvals and reauthorizations will be granted for 12 months

**References**  
1. Avastin (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech; May 2020  


7. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer


**Review History**
11/18/2020- Updated: moved Avastin to non-preferred, moved Mvasi and Zirabev to preferred for non-ocular diagnoses; moved to MB only; P+T reviewed

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.